Home » Topics » Disease categories and therapies » Infection

Infection
RSS

Cubist files IND to begin phase III clinical trials of daptomycin

Jan. 8, 1999

New antimalarial korupensamines available for licensing from NIH

Jan. 8, 1999

Bristol-Myers Squibb seeks approval for new antibiotic for respiratory and other infections

Jan. 7, 1999

Carbapenems in development at Sankyo

Jan. 7, 1999

Levofloxacin cleared for new indication by FDA

Jan. 5, 1999

Potent antimalarial activity demonstrated for diterpenoid produced by Okinawan sponge

Jan. 4, 1999

Antimalarial alkaloid compounds available for licensing from NIH

Jan. 4, 1999

Development of new beta-lactamase inhibitors revealed by Japanese laboratories

Dec. 30, 1998

Dura and Bristol-Myers Squibb sign exclusive license agreement

Dec. 28, 1998

Miltefosine evaluated clinically for the oral treatment of visceral leishmaniasis

Dec. 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...